R&D Navigating the unique challenges of epilepsy in women's heal... Epilepsy affects women differently than men, owing to the complexity of brain health and the historical lack of investment in women’s health.
R&D The glimmer of opportunity behind the storm: Ali Pashazadeh ... Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.
R&D The impact of generative AI on protein design for drug disco... Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.
R&D Changing the drug development treatment paradigm: Hilary Eat... Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.
R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
News CDC panel votes to scrap hepatitis B birth dose advice CDC advisers vote to overturn decades of US policy and abandon endorsement of universal hepatitis B vaccination for newborns in the US.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.